Senhwa Bio Taps AI Startup for Drug 2.0

The drug at the center of the deal, CX-4945, is also known by the name Silmitasertib. It's a first-in-class, orally available small molecule designed to inhibit protein kinase CK2, an enzyme that is often overexpressed in cancer cells and helps them survive and resist treatment. CX-4945's primary mechanism involves disrupting DNA repair pathways in cancer cells. This makes tumors more susceptible to the DNA-damaging effects of traditional chemotherapy and radiation, and the drug has been studied in combination with agents like gemcitabine and cisplatin. The drug has a long development history, with human clinical trials beginning as early as 2010. In January 2017, the U.S. Food and Drug Administration granted it Orphan Drug status for the treatment of cholangiocarcinoma, a type of bile duct cancer. CellType, the AI partner, was founded by computational biologist Dr. David van Dijk and is part of the Winter 2026 batch of the prestigious startup accelerator Y Combinator. The company's core technology was developed in a research collaboration between Yale University and Google DeepMind. The AI platform applies large language models to analyze single-cell gene expression data. This allows it to map out the complex cellular signals within a tumor's microenvironment, essentially creating a "virtual human" to simulate a drug's effect before it's given to a patient. This partnership isn't a first introduction. The foundational research behind CellType's AI had already computationally screened over 4,000 compounds and flagged CX-4945 for having a previously unknown immune-modulatory mechanism. That prediction was then experimentally validated in Yale laboratories, forming the basis for the new agreement.